HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Shanghai Henlius Biotech Update (2696.HK) - The Story Behind Privatization

Asia Cement China (743.HK) - Investors Are Facing the Dilemma of Low-Priced Privatization

CPMC Holdings (906.HK) Privatization - Some New Information Worth the Attention

Asia Cement (743 HK): $3.22/Share Offer - Really?

Equity Bottom-Up

<ul>
<li>New Horizon Health is a “big client” of Deloitte, who, however, still delay the publication of 2023 results. This leads us to take the issues raised by Deloitte more seriously.</li>
<li>It’s uncertain whether New Horizon Health would obtain the audit report with non-qualified opinion or "survive" the independent investigation.2023 Annual Report/2024 Mid-Year Report/2024 Annual Report may continue to be postponed.</li>
<li>If New Horizon Health fails provide reasonable explanation, investors don't need to spend any more time on the Company with no integrity.We forecast the timetable for the resumption of trading.</li>
</ul>


New Horizon Health is a “big client” of Deloitte, who, however, still delay the publication of 2023 results. This leads us to take the issues raised by Deloitte more seriously.
It’s uncertain whether New Horizon Health would obtain the audit report with non-qualified opinion or "survive" the independent investigation.2023 Annual Report/2024 Mid-Year Report/2024 Annual Report may continue to be postponed.
If New Horizon Health fails provide reasonable explanation, investors don't need to spend any more time on the Company with no integrity.We forecast the timetable for the resumption of trading.


New Horizon Health (6606 HK) - Behind the Trading Suspension and the Outlook